Molecular genetics of HBV infection, Antivir Ther, vol.15, p.324, 2010. ,
,
HBV life cycle: entry and morphogenesis, Viruses, vol.1, pp.185-209, 2009. ,
Molecular virology of hepatitis B virus for clinicians, Clin Liver Dis, vol.326, pp.685-706, 2007. ,
, , p.328
Identification of disubstituted sulfonamide compounds as specific inhibitors of hepatitis B 329 virus covalently closed circular DNA formation, Antimicrob Agents Chemother, vol.56, pp.4277-4288, 2012. ,
Emerging therapies toward a functional cure for hepatitis B virus infection, Gastroenterol, vol.331, 2018. ,
, Hepatol (N Y), vol.14, pp.439-442
Modulators of HBV capsid assembly as an approach to treating hepatitis B virus infection, 2016. ,
, Curr Opin Pharmacol, pp.131-137
The diverse functions of the hepatitis B 335 core/capsid protein (HBc) in the viral life cycle: implications for the development of HBc-targeting antivirals, 2018. ,
, Antiviral Res, vol.149, pp.211-220
Toward elimination of hepatitis B virus using novel 338 drugs, approaches, and combined modalities, Clin Liver Dis, vol.20, pp.737-749, 2016. ,
, , p.340
Preclinical characterization of GLS4, an inhibitor of hepatitis B virus core 341 particle assembly, Antimicrob Agents Chemother, vol.57, pp.5344-54, 2013. ,
Trapping of hepatitis B virus capsid assembly 343 intermediates by phenylpropenamide assembly accelerators, ACS Chem Biol, vol.5, pp.1125-1136, 2010. ,
, , p.345
Sulfamoylbenzamide derivatives inhibit the assembly of hepatitis B virus 346 nucleocapsids, J Virol, vol.87, pp.6931-6942, 2013. ,
Phase 348 1a safety and pharmacokinetics of NVR 3-778, a potential first-in-class HBV core inhibitor, LB19. b), vol.349, p.350, 2014. ,
Preclinical characterization of NVR 3-778, a first-in-class capsid assembly modulator 351 against hepatitis B virus, Antimicrob Agents Chemother, vol.63, pp.1734-1752, 2018. ,
, Fan, vol.353
, , p.354
, , vol.355
Preclinical profile of AB-423, an inhibitor of hepatitis B virus pregenomic RNA 356 encapsidation, Antimicrob Agents Chemother, vol.62, pp.82-100, 2018. ,
, , p.358
, , vol.360, p.17
Preclinical antiviral drug combination studies utilizing novel orally 361 bioavailable investigational agents for chronic hepatitis B infection: AB-506, a next generation HBV capsid 362 inhibitor, and AB-452, an HBV RNA destabilizer, J Hepatol, vol.68, p.17, 2018. ,
, , p.365
Interim safety, tolerability pharmacokinetics, 366 and antiviral activity of ABI-H0731, a novel core protein allosteric modulator, in healthy volunteers, and non-367 cirrhotic viremic subjects with chronic hepatitis B, J Hepatol, vol.68, p.111, 2018. ,
Synthesis of 369 sulfamoylbenzamide derivatives as HBV capsid assembly effector, Eur J Med Chem, vol.138, pp.407-421, 2017. ,
Development of a quantitative real-time 371 detection assay for hepatitis B virus DNA and comparison with two commercial assays, J Clin Microbiol, vol.372, pp.2897-2901, 2000. ,
Evaluation of 374 fluorescence-based thermal shift assays for hit identification in drug discovery, Anal Biochem, vol.332, pp.153-159, 2004. ,
-Aminothiophene-2, 4-dicarboxamide analogues as hepatitis B virus capsid assembly effectors, Eur. J. Med, vol.376, issue.5, 2019. ,
, Chem, vol.164, pp.179-192
Novel 382 potent capsid assembly modulators regulate multiple steps of the Hepatitis B virus life-cycle, 2018. ,
, , p.385
The heteroaryldihydropyrimidine Bay 386 38-7690 induces hepatitis B virus core protein aggregates associated with promyelocytic leukemia nuclear 387 bodies in infected cells, vol.3, pp.131-149, 2018. ,
Novel 389 non-heteroarylpyrimidine (HAP) capsid assembly modifiers have a different mode of action from HAPs in 390 vitro, Antivir. Res, vol.158, pp.135-177, 2018. ,
, , p.392
BAY 41-4109-mediated aggregation of assembled and 393 misassembled HBV capsids in cells revealed by electron microscopy, Antiv. Res, vol.169, p.104557, 2019. ,
, , p.395
Viral load affects 396 the immune response to HBV in mice with humanized immune system and liver, Gastroenterology, vol.153, pp.1647-397, 2017. ,
, , p.399
A novel mouse model for stable 400 engraftment of a human immune system and human hepatocytes, PLoS One, vol.10, p.119820, 2015. ,
, , p.402
, , vol.403, p.19
A novel orally available small molecule that 404 inhibits hepatitis B virus expression, J Hepatol, vol.68, pp.412-420, 2018. ,
Core protein: A 406 pleiotropic keystone in the HBV lifecycle, Antiviral Res, vol.121, pp.82-93, 2015. ,
,
Efficacy of NVR 3-778, Alone and in combination with pegylated Interferon, vs entecavir in 409 uPA/SCID mice with humanized livers and HBV infection, Gastroenterology, vol.154, pp.652-662, 2018. ,
, , p.411
Synthesis and evaluation of N-phenyl-3-412 sulfamoyl-benzamide derivatives as capsid assembly modulators inhibiting hepatitis B virus (HBV), J Med 413 Chem, vol.61, pp.6247-6260, 2018. ,
Serum hepatitis B 415 surface antigen levels predict surface antigen loss in hepatitis B e antigen seroconverters, Gastroenterology, vol.416, pp.511-512, 2011. ,
Discovery of hepatitis B virus 418 capsid assembly inhibitors leading to a heteroaryldihydropyrimidine based clinical candidate (GLS4), 2017. ,
, Med Chem, vol.25, pp.1042-1056
Inducible 421 expression of human hepatitis B virus (HBV) in stably transfected hepatoblastoma cells: a novel system for 422 screening potential inhibitors of HBV replication, Antimicrob Agents Chemother, vol.41, pp.1715-1720, 1997. ,
Hepatitis B virus e antigen production is 424 dependent upon covalently closed circular (ccc) DNA in HepAD38 cell cultures and may serve as a cccDNA 425 surrogate in antiviral screening assays, Antiviral Res, vol.72, pp.116-124, 2006. ,
Characterization of the intracellular 427 deproteinized relaxed circular DNA of hepatitis B virus: an intermediate of covalently closed circular DNA 428 formation, J Virol, vol.81, pp.12472-12484, 2007. ,
HBV cccDNA in patients' sera as an indicator for HBV reactivation and an 430 early signal of liver damage, 36. Roingeard P, Romet-Lemonne JL, vol.10, issue.1, p.431, 2004. ,
Hepatitis B virus core antigen (HBc Ag) accumulation in an HBV 432 nonproducer clone of HepG2-transfected cells is associated with cytopathic effect, Virology, vol.179, pp.113-120, 1990. ,
Combinations of 2'-C-methylcytidine analogues with 434 interferon-alpha2b and triple combination with ribavirin in the hepatitis C virus replicon system, Antivir, vol.435, 2008. ,
, Chem Chemother, vol.19, issue.1, pp.25-31